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LETTERS TO THE EDITOR
Peripheral blood
myeloperoxidase activity
increases during hemodialysis
To the Editor: In their paper, Pecoits-Filho et al [1]
show that a higher expression polymorphism in the pro-
moter region of myeloperoxidase (MPO) is associated with
cardiovascular disease in end-stage renal disease (ESRD)
patients. We have data that show that not only a genetic
polymorphism can result in higher MPO expression, but
that dialysis itself can also contribute to an increased MPO
activity. For this purpose, we measured the change in
neutrophil MPO activity (delta MPXI) pre- and postdial-
ysis in 54 patients and at a 4-hour interval in 12 healthy
control patients using an automated hematologic ana-
lyzer (ADVIA 120; Bayer, Tarrytown, NY, USA) [2].
Patients were dialyzed with polyamide or polysulfone
membranes using ultrapure dialysate. For comparison
between the two groups, nonparametric t testing was
performed. Bars represent the average change in MPXI
per group; error bars indicate 95% confidence intervals.
Thus, we found that dialysis, even with the use of bio-
compatible membranes and ultrapure dialysate, contrib-
utes to an increase of neutrophil MPO activity. Interest-
ingly, elevated levels of MPO are associated with the
presence of atherosclerosis [3], and increased MPO activity
can contribute to the proatherosclerotic actions of MPO,
including oxidation of low-density lipoprotein (LDL) and
consumption of nitric oxide [3].
Future studies should elucidate the role of increased
MPO activity in accelerated atherosclerosis of dialysis
patients.
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Albuminuria and renal
insufficiency prevalence
guides population screening
To the Editor: Garg et al [1] present the prevalence
of albuminuria and renal insufficiency from the National
Health and Nutrition Examination Survey (NHANES) III
between 1988 and 1994 as a guide to the number needed
to screen when considering early intervention to prevent
end-stage renal disease. The authors discuss the effects of
prescribing practices on such calculations, but analysis of
such effects was avoided due to the survey predating the
publication of studies demonstrating the efficacy of antihy-
pertensive therapy. The Australian Diabetes, Obesity and
Lifestyle Study, a population-representative study of 11,247
Australian adults was undertaken between 1999 and 2000,
and can provide some insights into the effect of current
use of antihypertensive therapy on the determination of
number needed to screen for albuminuria (Table 1) [2].
The prevalence of urine albumin to creatinine ratio 3.0
mg/mmol was significantly lower in the Australian survey
compared to NHANES III, except in the nondiabetic hy-
pertensive subgroup. Of individuals with albuminuria, lack
of antihypertensive therapy was reported in 61% overall:
48% of the diabetic subgroup, 41% of the nondiabetic,
hypertensive subgroup, and 100% of the nondiabetic,
nonhypertensive subgroup. The prevalence of albumin-
uria for all subgroups was significantly lower among indi-
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viduals not on antihypertensive therapy. Therefore, the
number needed to screen for albuminuria among individ-
uals not already receiving antihypertensive therapy is
significantly higher than that determined from NHANES
III. It is likely that more frequent use of antihypertensive
therapy has contributed to the lower prevalence of albu-
minuria in the Australian adult population of 1999 to
2000. These findings demonstrate the importance of con-
sidering concurrent use of interventions for the accurate
calculation of number needed to screen and consequent
assessment of effectiveness of screening.
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Reply from the Authors
We thank Drs. Briganti, Atkins, and Chadban for their
informative letter. As they mention, it is possible that
the differences in the prevalence of albuminuria between
the 1988 and 1994 American National Health and Nutri-
tion Examination Survey (NHANES) III [1] and the 1999–
2000 Australian AusDiab Kidney Study [2] result from
the increased use of antihypertensive therapy (supporting
the prediction we made in our paper). Differences be-
tween these studies may also relate to measurement tech-
niques, sampling methods, or population demographics. A
further consideration is whether the differences observed,
though statistically significant because of the large sample
size, are really clinically relevant. For example, in the
general population, the number needed to screen to iden-
tify one patient with an albumin to creatinine ratio greater
than 3.0 in AusDiab was 13 (95% confidence interval, 11
to 16), and in NHANES III was 11 (95% confidence
interval, 10 to 12).
The data provided by Briganti, Atkins, and Chadban
suggest that there are two methods by which secular in-
creases in antihypertensive therapy use (specifically, an-
giotensin-converting enzyme inhibitor and angiotensin re-
ceptor blocker use) may influence estimates of screening
effectiveness for prevention of end-stage renal disease
(ESRD); the number of patients who develop increased
serum creatinine or proteinuria may be reduced due to
effective therapy, and the number of patients in which
